Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Panic Disorder01:27

Panic Disorder

Panic disorder is an anxiety disorder characterized by recurrent and sudden minutes-long episodes of intense fear, known as panic attacks. These attacks may feel like heart attacks and often happen without warning or a specific cause. They can include symptoms such as rapid heart rate, shortness of breath, chest pain, trembling, sweating, dizziness, and a sense of helplessness. During a panic attack, individuals may feel as though they are experiencing a heart attack or are in a...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of polygenic risk scores and subphenotypes in social anxiety disorder.

Translational psychiatry·2026
Same author

Polygenic risk scores: en route to clinical practice.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V·2026
Same author

Polygenic risk scores in clinical applications - opportunities and challenges.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V·2026
Same author

A multi-source remote sensing dataset for large-scale forest monitoring.

Data in brief·2026
Same author

Clinical, Dietary, Lifestyle and Genetic Factors Associated With Age at Onset of Esophageal Adenocarcinoma.

United European gastroenterology journal·2026
Same author

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Jun 11, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

Serotonin transporter polymorphisms and panic disorder.

Johannes Schumacher1, Jürgen Deckert

  • 1Institute of Human Genetics, University of Bonn, Sigmund-Freud-Str, 25, 53127 Bonn, Germany. Johannes.Schumacher@uni-bonn.de.

Genome Medicine
|July 1, 2010
PubMed
Summary

Genetic factors contribute significantly to panic disorder (PD), a common anxiety disorder. Research suggests specific gene variants in the serotonin transporter gene SLC6A4 may increase PD risk.

More Related Videos

Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting
11:31

Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting

Published on: November 30, 2015

Related Experiment Videos

Last Updated: Jun 11, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting
11:31

Rapid Fractionation and Isolation of Whole Blood Components in Samples Obtained from a Community-based Setting

Published on: November 30, 2015

Area of Science:

  • Psychiatry
  • Genetics
  • Neuroscience

Background:

  • Panic disorder (PD) is a prevalent anxiety disorder with complex and not fully understood etiology.
  • Genetic factors account for approximately 48% of PD variance, indicating a significant hereditary component.
  • Family and twin studies suggest a complex genetic basis for the majority of PD cases.

Purpose of the Study:

  • To investigate the role of genetic factors in the pathophysiology of panic disorder.
  • To explore the association between specific gene polymorphisms and PD risk.
  • To examine the potential impact of SLC6A4 variants on gene expression and genotype-phenotype correlations.

Main Methods:

  • Review of existing family and twin studies on PD heritability.
  • Analysis of genetic association studies implicating polymorphisms in the serotonin transporter gene (SLC6A4).
  • Discussion of potential functional effects of SLC6A4 variants on gene expression.

Main Results:

  • Genetic factors are a major contributor to PD, explaining nearly half of the variance.
  • Polymorphisms at the 3' end of the SLC6A4 gene are promising candidates for PD risk variants.
  • Replication of these findings is needed to confirm their significance.

Conclusions:

  • The serotonin transporter gene SLC6A4 warrants further investigation for its role in PD.
  • Replication of observed associations and functional studies are crucial for understanding PD pathophysiology.
  • Identifying genetic risk factors may enable genotype-phenotype correlation studies in panic disorder.